Tenecteplase Thrombolytic Therapy for Acute Ischemic Stroke in China

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

1200 participants

Study Classification

OBSERVATIONAL

Study Start Date

2023-04-02

Study Completion Date

2024-05-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The objective of the study is to investigate the effectiveness and safety of rhTNK-tPA in acute ischemic stroke patients within 4.5 hours of symptom onset in a real-world clinical setting.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

CHinese Acute Tissue-Based Imaging Selection for Lysis In Stroke -Tenecteplase II

NCT04516993

Stroke

COMPLETED PHASE2

CHinese Acute Tissue-Based Imaging Selection for Lysis In Stroke -Tenecteplase

NCT04086147

Stroke

COMPLETED PHASE2

Efficacy and Safety of Tenecteplase Intravenous Thrombolysis in Acute Posterior Circulation Ischemic Stroke Within 4.5-24 Hours After Onset

NCT07094763

Acute Ischemic Stroke

NOT_YET_RECRUITING NA

Thrombolysis Treated With TNK-tPA in Acute Ischemic Stroke Patients （3T Stroke-II）

NCT05281549

Acute Ischemic Stroke

UNKNOWN PHASE2

Thrombolysis Treated With TNK-tPA in Acute Ischemic Stroke Patients （3T Stroke-Ⅲ）

NCT05745259

Acute Ischemic Stroke

UNKNOWN PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Recombinant human tenecteplase tissue-type plasminogen activator (rhTNK-tPA) has the logistic advantage of a single bolus infusion over recombinant tissue plasminogen activator (rt-PA) which needs a 1-hour infusion. The non-inferiority of rhTNK-tPA compared to rt-PA was proved by two recent randomized controlled clinical trials but the evidence is lacking regarding the real-world effectiveness and safety of rhTNK-tPA.

This is a multi-center, observational, retrospective study that enrolled acute ischemic stroke patients treated with rhTNK-tPA thrombolysis in China.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Ischemic Stroke

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Tenecteplase

acute ischemic stroke patients who receive intravenous thrombolysis with tenecteplase

Tenecteplase

Intervention Type DRUG

Thrombolysis wtih rhTNK-tPA

alteplase

acute ischemic stroke patients who receive intravenous thrombolysis with alteplase

Alteplase

Intervention Type DRUG

Thrombolysis wtih rt-PA

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Tenecteplase

Thrombolysis wtih rhTNK-tPA

Intervention Type DRUG

Alteplase

Thrombolysis wtih rt-PA

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

rhTNK-tPA rt-PA

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* all acute ischaemic stroke patients who met eligibility for thrombolysis with intravenous alteplase or TNK and presenting within 4·5 hours of symptom onset.